Hemostasis founders’ and scientists’ background is in filtration technology for numerous areas including medical, where the markets were largely advanced medical filtration, membrane manufacturing, blood filtration and numerous industrial filtration and separation technologies.
From the beginning of the pandemic, we recognized the need to reduce/eliminate aerosol plumes created during sinus surgery and we resolved to take on the challenge to this problem and create a solution for it, even though it’s not historically the focus of Hemostasis. We have welcomed this challenge and believe we have developed a very novel technology for the problem COVID as well as surgically generated smoke and aerosols which have created obstacles for many ENT surgeons, healthcare professionals, and institutions in general.
High-risk aerosol generating procedures (AGP) in sinus surgery include drills, electrocauterization, lasers, RF and harmonic scalpels. These generate aerosols and droplets .01-10 µm in size with the vast majority being in the <1 µm range. Viruses are typically in the .01 µm size range (SARS-CoV-19 is 0.06-0.14 µm). These are viable in surgically generated aerosols and smoke, although they are predominantly transmitted attached to larger aerosols. The SARS-CoV-2 can remain viable in aerosols for at least 3 hours. Smaller aerosols are considered to be the most harmful in that they can penetrate surgical masks and travel into the respiratory tract and alveoli.
For detailed information regarding indications for use, warnings and precautions, see Instructions for Use.